Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 13/20 | 0.48 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | LEF1 | Q9UJU2 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16396248 | 0.90 | HDAC1 (0.48) | HDAC1BCL2L1CA12CA1CA9 | |
| SCHEMBL6230442 | 0.84 | CA12 (0.47) | CA12CA1CA9LEF1CA2 | |
| SCHEMBL5201077 | 0.83 | CA12 (0.42) | HDAC1CA12CA1CA9LEF1 | |
| SCHEMBL22825030 | 0.80 | HDAC1 (0.56) | HDAC1 | |
| SCHEMBL22824938 | 0.77 | HDAC1 (0.43) | HDAC1BCL2L1CA12CA1CA9 | |
| SCHEMBL7078947 | 0.77 | HDAC1 (0.54) | HDAC1 | |
| SCHEMBL3968727 | 0.77 | CA12 (0.48) | HDAC1CA12CA1CA9LEF1 | |
| SCHEMBL14079744 | 0.76 | LDHA (0.67) | — | |
| SCHEMBL22825116 | 0.76 | HDAC1 (0.43) | HDAC1LEF1 | |
| SCHEMBL6113073 | 0.75 | KAT6A (0.48) | HDAC1CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196388-B2 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-02-05 | — | — | US | disclosed |
| US-10196388-B2 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-02-05 | — | — | US | disclosed |
| US-20180127409-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-10 | — | — | US | disclosed |
| US-20180127409-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-10 | — | — | US | disclosed |
| US-20180127409-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-10 | — | — | US | disclosed |
| US-9714242-B2 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-07-25 | — | — | US | disclosed |
| US-9714242-B2 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-07-25 | — | — | US | disclosed |
| US-9714242-B2 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-07-25 | — | — | US | disclosed |
| US-20150065537-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-03-05 | — | — | US | disclosed |
| US-20150065537-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-03-05 | — | — | US | disclosed |
| US-7732477-B2 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-08 | — | — | US | disclosed |
| US-7732477-B2 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-08 | — | — | US | disclosed |
| EP-1527073-B1 | BENZOTHIOPHENE UREA, BENZOFURANE UREA, AND INDOLE UREA, AND USE OF THE SAME AS ALPHA-7 ACHR AGONISTS | BAYER HEALTHCARE AG (DE) | 2007-08-22 | — | — | EP | disclosed |
| EP-1527073-B1 | BENZOTHIOPHENE UREA, BENZOFURANE UREA, AND INDOLE UREA, AND USE OF THE SAME AS ALPHA-7 ACHR AGONISTS | BAYER HEALTHCARE AG (DE) | 2007-08-22 | — | — | EP | disclosed |
| EP-1461335-B1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER HEALTHCARE AG (DE) | 2007-02-28 | — | — | EP | disclosed |
| EP-1461335-B1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER HEALTHCARE AG (DE) | 2007-02-28 | — | — | EP | disclosed |
| US-20060106096-A1 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | BAYER HEALTH AG (DE) | 2006-05-18 | — | — | US | disclosed |
| US-20050119325-A1 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | FMR LLC | 2005-06-02 | — | — | US | disclosed |
| EP-1461335-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | Bayer HealthCare AG (DE) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003055878-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER HEALTHCARE AG (DE) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065537-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | CHRNA7, CHRNA5, CHRNA4 | HDAC1 797/4885BCL2L1 2385/4885CA12 1938/4885 |
| US-20180127409-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | CHRNA7, CHRNA5, CHRNA4 | HDAC1 797/4885BCL2L1 2385/4885CA12 1938/4885 |
| US-20060106096-A1 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | CHRNA7, CHRNA5, CHRNA4 | HDAC1 695/4885BCL2L1 2402/4885CA12 1680/4885 |
| US-20050119325-A1 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | CHRNA2, CHRNA7, CHRNA3 | HDAC1 937/4885BCL2L1 3373/4885CA12 3307/4885 |
| US-10196388-B2 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | CHRNA7, CHRNA5, CHRNA4 | HDAC1 797/4885BCL2L1 2385/4885CA12 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.